IRON Disc Medicine, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—
Leverage & solvency
Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $170.64M | $96.67M |
| SG&A expense | $65.38M | $33.05M |
| Operating income | -$236.02M | -$129.72M |
| Interest expense | $3.61M | $572,000 |
| Pretax income | -$211.82M | -$109.00M |
| Income tax | $361,000 | $355,000 |
| Net income | -$212.18M | -$109.36M |
| EBITDA | -$235.74M | -$129.56M |
| EPS (basic) | -6.01 | -3.96 |
| EPS (diluted) | -6.01 | -3.96 |
| Weighted avg. shares (diluted) | 35.30M | 27.61M |
| Balance sheet | ||
| Cash & equivalents | $91.14M | $192.67M |
| Short-term investments | $700.01M | $297.45M |
| Current assets | $803.90M | $493.62M |
| PP&E, net | $1.16M | $751,000 |
| Total assets | $806.88M | $496.77M |
| Current liabilities | $36.64M | $23.32M |
| Long-term debt | $29.16M | $28.32M |
| Total debt | $29.16M | $28.32M |
| Total liabilities | $67.05M | $53.19M |
| Shareholders' equity | $739.83M | $443.59M |
| Net debt | -$61.99M | -$164.35M |
| Shares outstanding | 37.89M | 29.87M |
| Cash flow statement | ||
| Operating cash flow | -$180.39M | -$93.93M |
| Capital expenditure | $933,000 | $505,000 |
| Free cash flow | -$181.33M | -$94.43M |
| Investing cash flow | -$394.30M | -$292.33M |
| Financing cash flow | $473.41M | $218.31M |
| Depreciation & amortization | $281,000 | $156,000 |
| Stock-based compensation | $34.34M | $16.82M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.